多发性硬化患者那他珠单抗相关进行性多灶性白质脑病风险:四项临床研究数据的回顾性分析
该回顾性分析 pooled 四项观察性研究共 37 249 例那他珠单抗治疗的多发性硬化患者,其中 156 例(<1%)发生进行性多灶性白质脑病(PML)。抗JCV抗体指数可进一步分层无免疫抑制剂使用史患者的年度风险。
核心结论
- 基于患者水平临床数据的风险估计可用于个体化预测那他珠单抗治疗多发性硬化患者的年度 PML 风险,支持临床每年进行获益-风险评估。
- 抗JCV抗体指数可进一步对无既往免疫抑制剂使用的抗JCV抗体阳性患者进行风险分层。
研究设计与样本
- 回顾性分析,pooled 四项大型观察性开放标签研究(STRATIFY-2、STRATA、TOP、TYGRIS)的那他珠单抗治疗患者数据。
- 共纳入 37 249 例患者,其中 156 例(<1%)发生 PML;对缺失的抗JCV抗体状态(3912 例)和既往免疫抑制剂使用(544 例)采用多重插补法处理。
- 采用 Kaplan-Meier 法估计累积 PML 风险,基于生命表法的条件概率估计年度 PML 风险(每 12 次输注)。
临床怎么用
- 临床可基于抗JCV抗体状态、既往免疫抑制剂使用及治疗时长个体化预测年度 PML 风险。
- 建议每年重新评估那他珠单抗治疗的获益-风险。
- 对无既往免疫抑制剂使用的抗JCV抗体阳性患者,可结合抗体指数进一步分层风险。
局限性
- 为回顾性分析,数据来自观察性研究,可能存在混杂和缺失值。
- 缺失的抗JCV抗体状态和免疫抑制剂使用数据采用多重插补法处理。
- 抗体指数切点通过敏感性和特异性评估在指数队列中选定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Previous estimates of risk of progressive multifocal leukoencephalopathy (PML) in patients with multiple sclerosis receiving natalizumab were stratified by three risk factors: anti-John Cunningham virus (JCV) antibodies in serum, previous immunosuppressant use, and treatment duration, which were estimated using population-based assumptions. We aimed to calculate PML risk estimates from patient-level risk-factor data and to stratify risk by concentrations of anti-JCV antibody in serum (anti-JCV antibody index). METHODS: Data on natalizumab-treated patients were pooled from four large, observational, open-label studies: STRATIFY-2, STRATA, TOP, and TYGRIS. Data were analysed with and without imputation for missing values of anti-JCV antibody status and previous immunosuppressant use. For anti-JCV antibody-positive patients in this pooled cohort, cumulative PML risk with or without previous immunosuppressant use was estimated using Kaplan-Meier analysis. Annual PML risks (per 12 natalizumab infusions) for patients without PML in the preceding year were estimated using conditional probability based on the life table method. For anti-JCV antibody-positive patients without previous immunosuppressant use, risk estimates were further stratified using a probability distribution for anti-JCV antibody index values, separately for patients with or without PML. Anti-JCV antibody index cutoffs were selected via sensitivity and specificity assessments for identifying PML cases in an index cohort. FINDINGS: 156 (<1%) of 37 249 patients in the pooled cohort had PML. We imputed missing values on anti-JCV antibody status (3912 patients) and on previous immunosuppresant use (544 patients) using a multiple imputation method. For anti-JCV antibody-negative patients (n=13 996), estimated PML risk was less than 0·07 per 1000 patients (95% CI 0·00-0·40). In anti-JCV antibody-positive patients (n=21 696), estimated cumulative PML probability over 6 years (72 infusions of natalizumab) was 2·7% (95% CI 1·8-4·0) in patients with previous immunosuppressant use and 1·7% (1·4-2·1) in those without. In patients without previous immunosuppressant use (n=18 616), estimated annual PML risks per 1000 patients, conditional on having no PML before that year, ranged from 0·01 (0·00-0·03) in year 1 (1-12 infusions) to 0·6 (0·0-1·5) in year 6 (61-72 infusions) for people with an index of 0·9 or less; from 0·1 (0·0-0·2) in year 1 to 3·0 (0·2-5·8) in year 6 for those with an index of more than 0·9 up to and including 1·5; and from 0·2 (0·0-0·5) in year 1 to 10·0 (5·6-14·4) in year 6 for those with an index of more than 1·5. INTERPRETATION: Our risk estimates calculated from patient-level clinical data allow individualised annual prediction of risk of PML in patients receiving natalizumab for multiple sclerosis, supporting yearly benefit-risk re-evaluation in clinical practice. Further, our estimates are generally consistent with previously calculated estimates. Incorporating anti-JCV antibody index allows further risk stratification for anti-JCV antibody-positive patients who have not previously taken immunosuppressants. FUNDING: Biogen.
引用
- Ho PR, Koendgen H, Campbell N, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies. Lancet Neurol. 2017. PMID: 28969984. doi:10.1016/S1474-4422(17)30282-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。